59397-23-8

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Phenylcycloheptanamine is used as a precursor in the synthesis of various pharmaceuticals for its ability to be chemically modified and incorporated into different medicinal compounds.
Used in Organic Compound Manufacturing:
It serves as a key intermediate in the manufacturing of other organic compounds, highlighting its versatility in organic chemistry.
Used in Central Nervous System Research:
1-Phenylcycloheptanamine is used as a research chemical to study its potential role in the central nervous system, particularly as a stimulant, which can aid in understanding its effects and potential applications in neurobiology.
Used in Neurodegenerative Disorder Treatment:
It is being investigated for its potential use in treating Parkinson's disease and other neurodegenerative disorders, given its interactions with the central nervous system.
However, due to the limited understanding of its effects on the human body, 1-phenylcycloheptanamine must be handled with caution and under professional guidance to ensure safety and ethical use.

Upstream product

• 2082-21-5 1-phenylcycloheptanol 
• 108-86-1 bromobenzene 
• 100-58-3 phenylmagnesium bromide 
• 140-29-4 phenylacetonitrile 
• 65542-30-5 7-Brom-1-phenyl-1-heptancarbonitril 
• 502-42-1 cycloheptanone 

Downstream Products

• 79798-00-8 1-(1-phenylcycloheptyl)piperidine hydrochloride 
• 13683-43-7 N-cycloheptylidenebenzenamine 
• 231961-56-1 1-(1-phenylcycloheptyl)piperidin-4-one 
• 59358-72-4 1,1'-Diphenyl-1,1'-bicycloheptyl 

Relevant academic research and scientific papers

Azetidine derivatives and synthesis method thereof

The invention belongs to the field of chemical synthesis, and discloses an azetidine derivative and a synthesis method thereof. The structural formula of the target product azetidine derivatives is asshown in formulae (I), (II), (III), (IV) and (V). The compounds of the formulae are compounds containing an azetidine skeleton, and a nitrogen atom in the skeleton is protected by 2-picolinic acid. The target product azetidine derivatives can be: azetidinyl amide derivatives, azabicyclo[x.1.1] amide derivatives (x=3, 4, 5, 6, 7, 8, 9), azabicyclo[4.1.1] amide derivatives having a substituent at the ring, azabicyclo[4.2.0] amide derivatives and azetidine derivatives containing spirocyclic quaternary carbon. The azetidine derivatives of the present invention have certain protective effect on hydrogen peroxide-induced oxidative stress damage of HC cells.

Polycyclic Azetidines and Pyrrolidines via Palladium-Catalyzed Intramolecular Amination of Unactivated C(sp3)-H Bonds

A novel strategy to construct complex polycyclic nitrogen-containing heterocycles from aliphatic amines via picolinamide-assisted palladium-catalyzed C-H bond activation reaction was reported. The reaction exhibits broad substrate scope for the synthesis of various azabicyclic scaffolds, including azetidines and tropane-class alkaloids. Application of this method to naturally occurring (-)-cis-myrtanylamine, an unprecedented type of carbon-carbon bond activation, in which the electron-pair involved initiates an intramolecular "SN2-like" displacement of a cyclopalladium-fragment from a tertiary center, is described.

Syntheses and N-methyl-D-aspartate receptor antagonist pharmacology of fluorinated arylcycloheptylamines

Selective uncompetitive antagonists of the phencyclidine (PCP) binding site of the N-methyl-D-aspartate receptor (NMDAR) are known to have therapeutic potential as anticonvulsants and neuroprotective agents. Several fluorinated molecules with each containing a cycloheptane ring were designed to probe the PCP pharmacophore and test the influence of fluorine substitution on NMDAR binding and in vivo efficacy. Syntheses and analyses of six novel compounds, 1-(4-fluorophenyl)cycloheptanamine (3), 1-(1-(4-fluorophenyl)cycloheptyl)piperidine (4), 1-(1-(4-fluorophenyl)cycloheptyl) pyrrolidine (5), 1-(3-fluorophenyl)cycloheptanamine (6), 1-(1-(3-fluorophenyl)cycloheptyl)piperidine (7), 1-(1-(3-fluorophenyl)cycloheptyl)pyrrolidine (8) and several related reference arylcyloalkylamines are described. Receptor binding was performed at the PCP site of NMDAR for each compound using [3H]-(+)-MK-801 displacement. Unexpectedly, the 3-fluoro-primary amine 6 had the greatest affinity of the series and these binding results support a different structure activity relationship (SAR) profile for arylcycloheptylamines when compared to arylcyclohexylamines like PCP. Five of the novel compounds have affinity (Ki) in the hundred nM (10-7) range. In addition, compounds 3, 5, 6, 7 and 8 were evaluated and found to exhibit neuroprotective effects from NMDA induced toxicity in vitro and compounds 6, 7 and 8 exhibited anticonvulsant activities in rats. An ED50 of 13.84 mg/kg was found for compound 6 in rat maximal electroshock (MES) test with a protective index (PI) of 3.66 against ataxia. These results support further investigation of the arylcycloheptylamine class.

Synthesis and Anticonvulsant Activity of 1-Phenylcyclohexylamine Analogues

Thirty-eight analogues of 1-phenylcyclohexylamine (PCA), a phencyclidine (PCP) derivative, were examined for their activities in the mouse maximal electroshock (MES) seizure test and in a motor-toxicity assay.In addition, we determined the binding affinities of the compounds for PCP acceptor sites in rat brain membranes labeled with -1-piperidine.Many of the analogues were protective against MES seizures (ED50s of 4-41 mg/kg, ip) and all of these compounds caused motor toxicity.The potencies in the motor toxicity and MES seizure tests showed a moderate correlation with the affinities for PCP sites.Several analogues exhibited a greater separation of potencies in the motor toxicity and MES seizure tests than did the parent compound PCA.These were obtained by (i) 3-methylation of the cyclohexyl ring trans to the phenyl ring, (ii) methoxylation at the ortho position on the phenyl ring, and (iii) contraction of the cyclohexane ring to form the corresponding cyclopentane.